

Manuel Battegay

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5572584/manuel-battegay-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

351
papers

11,993
citations

55
h-index

98
g-index

369
ext. papers

13,907
ext. citations

6.7
avg, IF

5.79
L-index

#	Paper	IF	Citations
351	A qualitative study on safety perception among healthcare workers of a tertiary academic care center during the SARS-CoV-2 pandemic.. <i>Antimicrobial Resistance and Infection Control</i> , 2022 , 11, 30	6.2	0
350	Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area.. <i>Virus Evolution</i> , 2022 , 8, veac002	3.7	0
349	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. <i>Microorganisms</i> , 2022 , 10, 857	4.9	0
348	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1198-1208	7	3
347	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021 , 73, 195-202	11.6	2
346	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2145-e2152	11.6	3
345	Corrigendum to: Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2021 , 223, 734-735	7	1
344	Long-term outcome after SARS-CoV-2 infection in healthcare workers: a single centre cohort study. <i>Swiss Medical Weekly</i> , 2021 , 151, w30094	3.1	0
343	Exercise capacity-impairment after COVID-19 pneumonia is mainly caused by deconditioning. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
342	Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR). <i>Swiss Medical Weekly</i> , 2021 , 151, w30105	3.1	4
341	Morbidity associated with <i>Schistosoma mansoni</i> infection in north-eastern Democratic Republic of the Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009375	4.8	1
340	Epidemiology of <i>Schistosoma mansoni</i> infection in Ituri Province, north-eastern Democratic Republic of the Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009486	4.8	1
339	Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomized clinical trial. <i>PLoS Medicine</i> , 2021 , 18, e1003839	11.6	0
338	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021 , 17, e1009529	5	0
337	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 758-764	5.1	5
336	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021 , 106, 2233-2241	6.6	1
335	Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1231-1239	6.1	3

334	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Antigens. <i>Frontiers in Immunology</i> , 2021 , 12, 620622	8.4	2
333	SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event. <i>PLoS Pathogens</i> , 2021 , 17, e1009374	7.6	20
332	Immunophenotypic characterization of TCR α cells and MAIT cells in HIV-infected individuals developing Hodgkin's lymphoma. <i>Infectious Agents and Cancer</i> , 2021 , 16, 24	3.5	0
331	Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. <i>BMC Infectious Diseases</i> , 2021 , 21, 319	4	2
330	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021 , 35, 2025-2033	3.9	0
329	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. <i>Microorganisms</i> , 2021 , 9,	4.9	4
328	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25726	5.4	2
327	Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland - a retrospective single centre cohort study. <i>Swiss Medical Weekly</i> , 2021 , 151, w20572	3.1	5
326	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021 , 72, 2175-2183	11.6	2
325	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1413-1421	11.6	0
324	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 458-470	3.8	7
323	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 471-484	6.1	4
322	Mortality Rate in a Cohort of People Living With HIV in Rural Tanzania After Accounting for Unseen Deaths Among Those Lost to Follow-up. <i>American Journal of Epidemiology</i> , 2021 , 190, 251-264	3.8	2
321	Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. <i>Journal of Medical Virology</i> , 2021 , 93, 2374-2384	19.7	8
320	Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19. <i>Drug Safety</i> , 2021 , 44, 255-257	5.1	1
319	Prescribing in COVID-19 patients: Should we take into account inflammation?. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 719-721	3.8	
318	Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. <i>Journal of Intensive Care</i> , 2021 , 9, 10	7	27
317	Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. <i>Nature Communications</i> , 2021 , 12, 6	17.4	81

316	Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1025-1029	6.1	3
315	Systematic screening on admission for SARS-CoV-2 to detect asymptomatic infections. <i>Antimicrobial Resistance and Infection Control</i> , 2021 , 10, 44	6.2	6
314	Identifying and Characterizing Trans women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
313	Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2681-2689	5.1	1
312	Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study. <i>Swiss Medical Weekly</i> , 2021 , 151, w20550	3.1	3
311	Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature. <i>AIDS Research and Therapy</i> , 2021 , 18, 56	3	1
310	Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	4
309	Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0138121	9.7	6
308	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab032	1	5
307	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2021 ,	7.8	6
306	Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania.. <i>PLoS ONE</i> , 2021 , 16, e0261367	3.7	0
305	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020 , 11, 5542	17.4	2
304	Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study. <i>BMC Infectious Diseases</i> , 2020 , 20, 349	4	1
303	Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: A multicenter screening study in Lesotho. <i>Journal of Medical Virology</i> , 2020 , 92, 3857	19.7	1
302	Low rates of influenza vaccination uptake among healthcare workers: Distinguishing barriers between occupational groups. <i>American Journal of Infection Control</i> , 2020 , 48, 1139-1143	3.8	7
301	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3084-3086	5.1	10
300	Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25460	5.4	8
299	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort. <i>PLoS ONE</i> , 2020 , 15, e0229875	3.7	4

298	Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa185	1	25
297	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	35
296	High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania - A prospective cohort study. <i>PLoS ONE</i> , 2020 , 15, e0227600	3.7	3
295	Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa019	1	7
294	Real-life management of drug-drug interactions between antiretrovirals and statins. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1972-1980	5.1	5
293	Aging does not impact drug-drug interaction magnitudes with antiretrovirals. <i>Aids</i> , 2020 , 34, 949-952	3.5	1
292	Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study. <i>Blood</i> , 2020 , 136, 29-30	2.2	3
291	Characterising the epidemic spread of influenza A/H3N2 within a city through phylogenetics. <i>PLoS Pathogens</i> , 2020 , 16, e1008984	7.6	5
290	COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. <i>Swiss Medical Weekly</i> , 2020 , 150, w20225	3.1	262
289	Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft. <i>Swiss Medical Weekly</i> , 2020 , 150, w20271	3.1	45
288	Early off-label treatment during pandemics? A dilemma. <i>Swiss Medical Weekly</i> , 2020 , 150, w20281	3.1	2
287	Schistosomiasis: from established diagnostic assays to emerging micro/nanotechnology-based rapid field testing for clinical management and epidemiology. <i>Precision Nanomedicine</i> , 2020 , 3, 439-458	1.2	3
286	Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray 2020 ,		40
285	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020 , 147, 757-765	7.5	3
284	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020 , 34, 103-108	3.5	14
283	COVID-19 Triage and Test Center: Safety, Feasibility, and Outcomes of Low-Threshold Testing. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
282	Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. <i>BMJ Open</i> , 2020 , 10, e040110	3	3
281	Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1270-1279	7	33

280	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 517-524	3.1	3
279	Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial. <i>Lancet HIV, the</i> , 2020 , 7, e752-e761	7.8	11
278	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. <i>PLoS Medicine</i> , 2020 , 17, e1003325	11.6	7
277	Are three antiseptic paints needed for safe preparation of the surgical field? A prospective cohort study with 239 patients. <i>Antimicrobial Resistance and Infection Control</i> , 2020 , 9, 120	6.2	1
276	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 383-401	6.2	15
275	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho 2020 , 17, e1003325		
274	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho 2020 , 17, e1003325		
273	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho 2020 , 17, e1003325		
272	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho 2020 , 17, e1003325		
271	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort 2020 , 15, e0229875		
270	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort 2020 , 15, e0229875		
269	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort 2020 , 15, e0229875		
268	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort 2020 , 15, e0229875		
267	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort 2020 , 15, e0229875		
266	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort 2020 , 15, e0229875		
265	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. <i>Studies in Health Technology and Informatics</i> , 2020 , 270, 1163-1167	0.5	0
264	Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania. <i>BMC Research Notes</i> , 2019 , 12, 561	2.3	
263	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1224-1228	3.4	6

262	Sonography to Rule Out Tuberculosis in Sub-Saharan Africa: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz154	1	8
261	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019 , 393, 2428-2438	40	363
260	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019 , 220, 244-253	7	4
259	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019 , 220, 254-265	7	10
258	Plea for Standardized Reporting and Justification of Propensity Score Methods. <i>Clinical Infectious Diseases</i> , 2019 , 68, 710-711	11.6	2
257	Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 827-833	11.6	4
256	Impact of health insurance status on surgical site infection incidence: A prospective cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2019 , 40, 1063-1065	2	
255	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. <i>Nature Communications</i> , 2019 , 10, 3193	17.4	50
254	Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. <i>BMC Infectious Diseases</i> , 2019 , 19, 821	4	6
253	Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. <i>Mycoses</i> , 2019 , 62, 1127-1132	5.2	4
252	Identification of influenza urban transmission patterns by geographical, epidemiological and whole genome sequencing data: protocol for an observational study. <i>BMJ Open</i> , 2019 , 9, e030913	3	3
251	The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. <i>Swiss Medical Weekly</i> , 2019 , 149, w20059	3.1	1
250	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz531	1	17
249	Age-related comorbidities and mortality in people living with HIV in rural Tanzania. <i>Aids</i> , 2019 , 33, 1031-1041	3.5	8
248	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 508-515	3.1	
247	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 483-501	6.2	31
246	High Mortality of Non-Fournier Necrotizing Fasciitis With Enterobacteriales: Time to Rethink Classification?. <i>Clinical Infectious Diseases</i> , 2019 , 69, 147-150	11.6	5
245	Frequent Door Openings During Cardiac Surgery Are Associated With Increased Risk for Surgical Site Infection: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 290-294	11.6	18

244	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
243	Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy072	1	5
242	Digging Out the Evidence-How Strong Is the IDSA Recommendation Against Antibiotic Prophylaxis in Basilar Skull Fracture and Cerebrospinal Fluid Leakage?. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1319-1320	11.6	1
241	Direct Costs of a Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 101-103	2	21
240	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 598-607	9.7	7
239	Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2729-2737	5.1	11
238	Costs versus earnings in colon surgery and coronary artery bypass grafting under a prospective payment system: Sufficient financial incentives to reduce surgical site infections?. <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 1246-1249	2	2
237	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018 , 36, 757-764	1.3	3
236	Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods. <i>Aids</i> , 2018 , 32, 1903-1905	3.5	3
235	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018 , 4, vey024	3.7	16
234	Introduction to Machine Learning in Digital Healthcare Epidemiology. <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 1457-1462	2	28
233	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018 , 35, 27-37	8.3	19
232	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018 , 561, 406-410	50.4	37
231	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018 , 215, 1589-1608	16.6	23
230	Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study. <i>Kidney International Reports</i> , 2018 , 3, 1089-1099	4.1	4
229	Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2574-2577	5.1	5
228	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1275-1278	11.6	12
227	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2069-2074	5.1	5

226	Increasing prevalence of infectious diseases in asylum seekers at a tertiary care hospital in Switzerland. <i>PLoS ONE</i> , 2017 , 12, e0179537	3.7	23
225	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. <i>PLoS ONE</i> , 2017 , 12, e0180983	3.7	19
224	Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2017 , 17, 476	4	7
223	Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania: The One Stop Clinic model. <i>PLoS ONE</i> , 2017 , 12, e0181096	3.7	19
222	Specificity of two HIV screening tests detecting simultaneously HIV-1 p24 antigen and antibodies to HIV-1 and -2. <i>Journal of Virological Methods</i> , 2017 , 249, 143-146	2.6	7
221	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. <i>Medicine (United States)</i> , 2017 , 96, e5849	1.8	25
220	Dolutegravir plasma levels after gastric bypass surgery. <i>Aids</i> , 2017 , 31, 1052-1054	3.5	6
219	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017 , 66, 297-303	13.4	58
218	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 409-420	6.2	15
217	Previous exposure in a high-risk area for travellersQdiarrhoea within the past year is associated with a significant protective effect for travellersQdiarrhoea: a prospective observational cohort study in travellers to South Asia. <i>Journal of Travel Medicine</i> , 2017 , 24,	12.9	7
216	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017 , 6,	8.9	13
215	Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. <i>PLoS ONE</i> , 2017 , 12, e0172089	3.7	30
214	The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in Staphylococcus aureus bloodstream infection: A single-centre observational study. <i>PLoS ONE</i> , 2017 , 12, e0175669	3.7	2
213	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. <i>Swiss Medical Weekly</i> , 2017 , 147, w14485	3.1	21
212	Value of the Pitt Bacteraemia Score to predict short-term mortality in Staphylococcus aureus bloodstream infection: a validation study. <i>Swiss Medical Weekly</i> , 2017 , 147, w14482	3.1	7
211	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016 , 64, 1856-1869 ^{11,2}		61
210	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016 , 51, 97-102	10.5	12
209	Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Cohort Study. <i>Critical Care Medicine</i> , 2016 , 44, 773-81	1.4	12

208	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 63, 821-829	11.6	35
207	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016 , 214, 599-606	7	26
206	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw022	1	12
205	A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofv199	1	3
204	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3
203	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1310-1317	11.6	39
202	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 115-122	11.6	43
201	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw162	1	16
200	Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 1862-1870	9.7	70
199	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016 , 214, 399-402	7	31
198	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15
197	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016 , 22, 1260-1267	50.5	99
196	Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. <i>International Journal of STD and AIDS</i> , 2015 , 26, 212-4	1.4	5
195	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015 , 212, 578-84	7	17
194	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015 , 29, 193-200	3.5	9
193	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015 , 15, 79	3	16
192	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3323-31	5.1	5
191	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. <i>Cytotherapy</i> , 2015 , 17, 1280-91	4.8	4

190	A diagnostic HIV-1 tropism system based on sequence relatedness. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 597-610	9.7	7
189	Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 467-77	2.9	7
188	Limitations in study on benefits of clindamycin. <i>Clinical Infectious Diseases</i> , 2015 , 60, 323	11.6	1
187	Ebola vaccination. <i>Lancet, The</i> , 2015 , 386, 2478-80	40	
186	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv108	1	31
185	HIV resistance testing and detected drug resistance in Europe. <i>Aids</i> , 2015 , 29, 1379-89	3.5	12
184	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015 , 29, 2195-200	3.5	47
183	The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. <i>Aids</i> , 2015 , 29, 2509-15	3.5	60
182	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20317	5.4	41
181	A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. <i>PLoS ONE</i> , 2015 , 10, e0123275	3.7	19
180	Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 391-6	4.4	8
179	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv046	1	55
178	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015 , 15, 382	4	21
177	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015 , 212, 28-38	7	49
176	Disseminated tuberculosis in an HIV-infected child: rifampicin resistance detected by GeneXpert in a lymph node aspirate but not in cerebrospinal fluid. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	1
175	Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART--a case series over 11 years in a cohort of 1,153 patients. <i>Swiss Medical Weekly</i> , 2015 , 145, w14135	3.1	6
174	Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. <i>Journal of Infectious Diseases</i> , 2014 , 210, 1555-61	7	13
173	Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2363-8	5.9	26

172	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1312-21	11.6	107
171	Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1420-8	11.6	4
170	Does HIV antiretroviral therapy still need its backbone?. <i>Lancet, The</i> , 2014 , 384, 1908-10	4.0	4
169	Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. <i>HIV Clinical Trials</i> , 2014 , 15, 92-103		4
168	Choice of initial therapy. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19488	5.4	1
167	Disentangling human tolerance and resistance against HIV. <i>PLoS Biology</i> , 2014 , 12, e1001951	9.7	36
166	IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. <i>PLoS Pathogens</i> , 2014 , 10, e1004556	7.6	72
165	A short tool to screen HIV-infected patients for mild neurocognitive disorders - a pilot study. <i>BMC Psychology</i> , 2014 , 2, 21	2.8	3
164	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , 2014 , 28, 2565-71	3.5	9
163	Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014 , 58, 285-94	11.6	67
162	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014 , 43, 887-96	7.8	27
161	Vaccine adjuvants--understanding molecular mechanisms to improve vaccines. <i>Swiss Medical Weekly</i> , 2014 , 144, w13940	3.1	20
160	Surgical and antimicrobial treatment of prosthetic vascular graft infections at different surgical sites: a retrospective study of treatment outcomes. <i>PLoS ONE</i> , 2014 , 9, e112947	3.7	51
159	Enterococci, Clostridium difficile and ESBL-producing bacteria: epidemiology, clinical impact and prevention in ICU patients. <i>Swiss Medical Weekly</i> , 2014 , 144, w14009	3.1	18
158	Symptom manageability in Swiss HIV-infected patients. <i>Applied Nursing Research</i> , 2013 , 26, 110-5	1.8	3
157	The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. <i>Molecular Pharmaceutics</i> , 2013 , 10, 2340-9	5.6	14
156	The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. <i>PLoS Computational Biology</i> , 2013 , 9, e1003203	5	17
155	HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. <i>PLoS Genetics</i> , 2013 , 9, e1003318	6	61

154	The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/ μ l in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1038-47	11.6	79
153	Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania. <i>PLoS ONE</i> , 2013 , 8, e58468	3.7	30
152	Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. <i>PLoS ONE</i> , 2013 , 8, e51983	3.7	8
151	Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change. <i>Swiss Medical Weekly</i> , 2013 , 143, w13775	3.1	14
150	Role of retroviral restriction factors in the interferon- β -mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 3035-40	11.5	107
149	Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. <i>Clinical Infectious Diseases</i> , 2012 , 54, 131-40	11.6	30
148	Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 388-95	9.7	37
147	Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy. <i>Aids</i> , 2012 , 26, 1449-50	3.5	0
146	Lung resection in hematologic patients with pulmonary invasive fungal disease. <i>Chest</i> , 2012 , 142, 988-995	5.3	15
145	Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. <i>Antiviral Therapy</i> , 2012 , 17, 1381-4	1.6	13
144	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. <i>Aids</i> , 2012 , 26, 567-75	3.5	63
143	No risk of surgical site infections from residual bacteria after disinfection with povidone-iodine-alcohol in 1014 cases: a prospective observational study. <i>Annals of Surgery</i> , 2012 , 255, 565-9	7.8	25
142	Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. <i>PLoS ONE</i> , 2012 , 7, e29186	3.7	21
141	Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF- κ B activation. <i>PLoS ONE</i> , 2012 , 7, e32168	3.7	15
140	A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011 , 6, e27903	3.7	16
139	Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. <i>Antiviral Therapy</i> , 2011 , 16, 535-45	1.6	65
138	Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. <i>Clinical Therapeutics</i> , 2011 , 33, 1308-20	3.5	10
137	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011 , 53, 1446-54	11.2	53

136	Emergence of glutaraldehyde-resistant <i>Pseudomonas aeruginosa</i> . <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 1173-8	2	17
135	The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1095-103	7	60
134	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. <i>Aids</i> , 2011 , 25, 441-51	3.5	30
133	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2107-11	5.1	109
132	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011 , 60, 1506-19	19.2	52
131	Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1130-9	11.6	433
130	Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. <i>Clinical Infectious Diseases</i> , 2011 , 52, 532-9	11.6	99
129	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2391-400	15.9	144
128	Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. <i>PLoS ONE</i> , 2011 , 6, e27463	3.7	41
127	Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. <i>Tropical Medicine and International Health</i> , 2010 , 15, 567-73	2.3	18
126	A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 1799-806	5.1	29
125	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010 , 59, 1252-8	19.2	39
124	Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 997-1005	1.6	9
123	Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. <i>Clinical Infectious Diseases</i> , 2010 , 50, 502-11	11.6	77
122	Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. <i>PLoS Pathogens</i> , 2010 , 6, e1001123	7.6	91
121	Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?. <i>Aids</i> , 2010 , 24, 1057-9	3.5	2
120	Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. <i>American Journal of Psychiatry</i> , 2010 , 167, 143-50	11.9	84
119	Extended spectrum β -lactamase-producing <i>Escherichia coli</i> in neonatal care unit. <i>Emerging Infectious Diseases</i> , 2010 , 16, 1758-60	10.2	30

118	Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. <i>Aids</i> , 2010 , 24, 2287-9	3.5	8
117	HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. <i>Aids</i> , 2010 , 24, 2758-60	3.5	3
116	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010 , 15, 413-23	1.6	134
115	Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010 , 15, 31-40	1.6	9
114	JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. <i>Journal of Virology</i> , 2009 , 83, 4404-11	6.6	64
113	Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1459-66	11.6	100
112	Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009 , 48, 979-87	11.6	41
111	Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. <i>Circulation: Cardiovascular Genetics</i> , 2009 , 2, 621-8		32
110	Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. <i>American Journal of Kidney Diseases</i> , 2009 , 54, e1-4	7.4	29
109	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 632-41	5.7	13
108	Outcomes of early switching from intravenous to oral antibiotics on medical wards. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 188-99	5.1	94
107	Scabies outbreak in an intensive care unit with 1,659 exposed individuals--key factors for controlling the outbreak. <i>Infection Control and Hospital Epidemiology</i> , 2009 , 30, 354-60	2	42
106	A pain in the neck: probiotics for ulcerative colitis. <i>Annals of Internal Medicine</i> , 2009 , 151, 895-7	8	10
105	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009 , 14, 771-9	1.6	8
104	Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. <i>HIV Clinical Trials</i> , 2009 , 10, 207-14		2
103	Hodgkin lymphoma in the Swiss HIV Cohort Study. <i>Blood</i> , 2009 , 113, 5737-42	2.2	80
102	Safety and efficacy of once-daily nevirapine dosing: a multicohort study. <i>Antiviral Therapy</i> , 2009 , 14, 931-86		18
101	Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. <i>PLoS ONE</i> , 2009 , 4, e8275	3.7	16

100	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009 , 14, 349-357	1.6	32
99	Round-table multidisciplinary counselling of couples with HIV prior to assisted reproduction. <i>Reproductive BioMedicine Online</i> , 2008 , 17, 167-74	4	4
98	Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. <i>Clinical Infectious Diseases</i> , 2008 , 47, 73-82	11.6	188
97	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>Aids</i> , 2008 , 22, 301-6	3.5	107
96	Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1685-94	7	83
95	Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1299-309	11.6	29
94	HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1921-5	11.6	24
93	CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1093-101	11.6	41
92	Antiretroviral therapy of late presenters with advanced HIV disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 41-4	5.1	114
91	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008 , 22, 767-75	3.5	35
90	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008 , 22, 1463-73	3.5	173
89	Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008 , 38, 2665-77	6.1	112
88	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. <i>Antiviral Therapy</i> , 2008 , 13, 77-86	1.6	81
87	HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. <i>PLoS Medicine</i> , 2007 , 4, e96	11.6	65
86	Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. <i>Aids</i> , 2007 , 21, 1977-80	3.5	16
85	Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. <i>Aids</i> , 2007 , 21, 939-46	3.5	26
84	Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. <i>HIV Clinical Trials</i> , 2007 , 8, 77-85		7
83	Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma. <i>Aids</i> , 2007 , 21, 1664-6	3.5	3

82	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2007 , 81, 8846-8848	6.6	1
81	Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era. <i>Aids</i> , 2007 , 21, 537-8	3.5	1
80	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007 , 21, 2201-7	3.5	6
79	TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents. <i>American Journal of Medicine</i> , 2007 , 120, 350-6	2.4	34
78	Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. <i>PLoS ONE</i> , 2007 , 2, e173	3.7	24
77	Late presentation of HIV-infected individuals. <i>Antiviral Therapy</i> , 2007 , 12, 841-51	1.6	24
76	Late Presentation of HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2007 , 12, 841-851	1.6	34
75	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 931-940	1.6	20
74	CD4+ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 889-898	1.6	18
73	Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. <i>Journal of Virology</i> , 2006 , 80, 11094-104	6.6	98
72	Immunological recovery and antiretroviral therapy in HIV-1 infection. <i>Lancet Infectious Diseases, The</i> , 2006 , 6, 280-7	25.5	188
71	Clinical spectrum of the immune restoration inflammatory syndrome. <i>Current Opinion in HIV and AIDS</i> , 2006 , 1, 56-61	4.2	10
70	Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. <i>Aids</i> , 2006 , 20, 129-31	3.5	2
69	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006 , 11, 305-314	1.6	5
68	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006 , 11, 131-142	1.6	22
67	A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. <i>Antiviral Therapy</i> , 2006 , 11, 787-796	1.6	45
66	Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo. <i>Journal of Hepatology</i> , 2005 , 42, 150-2	13.4	1
65	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005 , 19, 1987-94	3.5	25

64	Symptom management in HIV/AIDS: advancing the conceptualization. <i>Advances in Nursing Science</i> , 2005 , 28, 333-44	2.1	39
63	Characteristics, determinants, and clinical relevance of CD4 T cell recovery to . <i>Clinical Infectious Diseases</i> , 2005 , 41, 361-72	11.6	257
62	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005 , 10, 585-591	1.6	67
61	Body Fat Changes among Antiretroviral-Naive Patients on Pi- and Nnrti-Based Haart in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005 , 10, 73-81	1.6	19
60	Intranasal influenza vaccine in a working population. <i>Clinical Infectious Diseases</i> , 2004 , 38, 974-80	11.6	28
59	Sexual risk behavior in HIV-infected injection drug users. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1175-7	11.6	7
58	Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. <i>Clinical Infectious Diseases</i> , 2004 , 38, e32-5	11.6	52
57	Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 303-5	5.1	7
56	Immune reconstitution in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1159-66	11.6	281
55	Carriage of Staphylococcus aureus among injection drug users: lower prevalence in an injection heroin maintenance program than in an oral methadone program. <i>Infection Control and Hospital Epidemiology</i> , 2004 , 25, 133-7	2	18
54	The decision to get vaccinated against influenza. <i>American Journal of Medicine</i> , 2004 , 116, 856-8	2.4	10
53	Chest pain after travel to the tropics. <i>Lancet, The</i> , 2004 , 363, 1198	4.0	7
52	Productivity costs and determinants of productivity in HIV-infected patients. <i>Clinical Therapeutics</i> , 2004 , 26, 791-800	3.5	20
51	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. <i>Aids</i> , 2004 , 18, 1521-7	3.5	22
50	Is unsafe sexual behaviour increasing among HIV-infected individuals?. <i>Aids</i> , 2004 , 18, 1707-14	3.5	24
49	Gynecomastia and potent antiretroviral therapy. <i>Aids</i> , 2004 , 18, 1347-9	3.5	9
48	All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. <i>Aids</i> , 2004 , 18, 1835-43	3.5	68
47	Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. <i>Antiviral Therapy</i> , 2004 , 9, 453-9	1.6	2

46	EpsteinBarr Virus Load Correlating with Clinical Manifestation and Treatment Response in a Patient with Angioimmunoblastic T-Cell Lymphoma. <i>Antiviral Therapy</i> , 2004 , 9, 453-459	1.6	12
45	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004 , 9, 263-274	1.6	5
44	Infrequent Transmission of HIV-1 Drug-Resistant Variants. <i>Antiviral Therapy</i> , 2004 , 9, 375-384	1.6	40
43	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. <i>Aids</i> , 2003 , 17, 2237-44	3.5	61
42	Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. <i>Aids</i> , 2003 , 17, 2451-9	3.5	38
41	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet, The</i> , 2003 , 362, 877-8	4.0	91
40	Intravenous opiate maintenance in a cohort of injecting drug addicts. <i>Drug and Alcohol Dependence</i> , 2003 , 69, 183-8	4.9	10
39	Evaluation of unstructured medical school examinations: prospective observational study. <i>Swiss Medical Weekly</i> , 2003 , 133, 184-7	3.1	4
38	Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case. <i>Diseases of the Colon and Rectum</i> , 2002 , 45, 977-8	3.1	26
37	Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. <i>Clinical Infectious Diseases</i> , 2002 , 34, 711-3	11.6	20
36	Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 1303-13	5.9	5
35	Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. <i>Lancet, The</i> , 2002 , 359, 2230-4	4.0	61
34	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002 , 16, 1967-9	3.5	88
33	Evidence for prevention and screening: recommendations in adults. <i>Swiss Medical Weekly</i> , 2002 , 132, 363-73	3.1	4
32	Onset and pattern of substance use in intravenous drug users of an opiate maintenance program. <i>Drug and Alcohol Dependence</i> , 2001 , 64, 105-9	4.9	20
31	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , 2001 , 358, 1322-7	4.0	280
30	Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. <i>Aids</i> , 2000 , 14, 791-9	3.5	30
29	Discontinuation of primary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. <i>New England Journal of Medicine</i> , 1999 , 340, 1301-6	59.2	235

28	Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 811-7	5.1	24
27	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 2220-6	27.4	341
26	General and specific immunosuppression caused by antiviral T-cell responses. <i>Immunological Reviews</i> , 1999 , 168, 305-15	11.3	45
25	Salvage treatment against human immunodeficiency virus. <i>Annals of Medicine</i> , 1999 , 31, 253-60	1.5	9
24	Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 803-10	1.6	36
23	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. <i>Lancet, The</i> , 1999 , 353, 863-8	4.0	812
22	Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. <i>Aids</i> , 1999 , 13, 501-7	3.5	185
21	Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. <i>Aids</i> , 1999 , 13, 1587-9	3.5	19
20	HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for Toxoplasma gondii, Epstein-Barr virus, and JC virus. <i>Clinical Microbiology and Infection</i> , 1998 , 4, 577-584	9.5	19
19	Is CD95 or CD26 expression on T-cells a marker for HIV non- or slow-progressor status?. <i>Clinical Microbiology and Infection</i> , 1998 , 4, 464-465	9.5	
18	Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. <i>FEBS Journal</i> , 1998 , 254, 514-9		50
17	Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. <i>Aids</i> , 1998 , 12, 2115-23	3.5	78
16	Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 1998 , 10, 75-9	2.2	12
15	High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. <i>Journal of Hepatology</i> , 1997 , 26, 794-7	13.4	51
14	Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine. <i>Clinical Microbiology and Infection</i> , 1997 , 3, 629-633	9.5	
13	Erythema of the proximal nailfold in HIV-infected patients. <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, 631-3	4.5	31
12	Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. <i>Cellular Immunology</i> , 1996 , 167, 115-21	4.4	44
11	Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice. <i>European Journal of Immunology</i> , 1996 , 26, 250-8	6.1	11

10	Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 1583-8	4	31
9	Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. <i>Journal of Medical Virology</i> , 1994 , 44, 389-92	19.7	34
8	Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis. <i>Digestive Diseases and Sciences</i> , 1994 , 39, 2650-5	4	8
7	Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins. <i>European Journal of Immunology</i> , 1993 , 23, 1540-5	6.1	15
6	Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells. <i>European Journal of Immunology</i> , 1993 , 23, 3236-41	6.1	32
5	Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. <i>Journal of Virological Methods</i> , 1991 , 33, 191-8	2.6	379
4	Exploring the doctor-patient relationship reduces staff stress and enhances empathy when caring for AIDS patients. <i>Psychotherapy and Psychosomatics</i> , 1991 , 56, 167-73	9.4	8
3	SARS-CoV-2 phylogeny during the early outbreak in the Basel area, Switzerland: import and spread dominated by a single B.1 lineage variant (C15324T)		6
2	Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area		8
1	Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase		1